364 PATENT ABSTRACTS

parasite or other whole microorganism. The complex of antigen coupled to antibody may be used in immunizing a higher animal against an antigen.

5173294

D N A P R O B E F O R T H E I D E N T I F I C A T I O N O F

H A E M O P H I L U S I N F L U E N Z A E

Timothy F Murphy, Michael A Apicella as- signed to Research Foundation of State Univer- sity of New York

A plasmid which contains a genetic code for an immunogenic portion which is conserved in many strains of nontypable Haemophilus in- fluenzae and the bacterium containing this plas- mid is disclosed. The immunogenic portion is preferably an epitope on an outer membrane protein of H. influenzae. A monoclonal anti- body to the immunogenic portion and the hybridoma which will produce the monoclonal antibody is also included. The invention further includes a DNA probe constructed to cor- respond to the nucleic acids which code for the immunogenic portion. This probe may be label- led with a radioactive marker and may be used as a diagnostic tool to assay various clinical sam- ples for the presence of H. influenzae.

5173399

M O U S E M O N O C L O N A L A N T I B O D I E S T O H I V - I P 2 4 A N D

T H E I R U S E I N D I A G N O S T I C T E S T S

Smriti U Mehta, Jeffrey C Hunt, Sushil G Devare assigned to Abbott Laboratories

The present invention provides monoclonal antibodies demonstrating specific reactivity with HIV-1 p24. One monoclonal antibody designated 31-42-19 recognizes an unique epit- ope on HIV-I p24 that is not immunogenic in humans. 31-42-19 also reacts with an anti- genicaUy cross reactive epitope on HIV-2 p24. Another monoclonal antibody designated 31- 90-25 recognizes an epitope within a highly immunogenic region of HIV-I p24. The present invention also provides cell lines capable of pro- ducing these monoclonal antibodies. The inven- tion also includes a highly sensitive enzyme immunoassay for the detection of HIV-I p24 in

biological fluids, using a monoclonal antibody mixture. The present invention further provides methods for the use of these monoclonal anti- bodies for the detection of anti-HIV-1 p24 anti- bodies and HIV-2 p24 antigen in biological samples.

5173415

P R O C E S S F O R R E M O V A L O F V I R U S E S F R O M S O L U T I O N S O F

P H Y S I O L O G I C A L L Y A C T I V E S U B S T A N C E S

Hajim Hiratani, Jun Tateishi, Tetsuyuki Kitamoto, Sennan, Japan assigned to Japan Chemical Research Co Ltd

A membrane filter of 0.025 to 0.05 mu in pore size is treated by passing the solution of a water- soluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, poly- sorbate 80, gelatin or the like through the mem- brane filter. Employing the filter thus treated, the solution of a physiologically active substance of human origin such as human growth hor- mone, kallikrein, trypsin inhibitor, epidermal growth factor, leucocyte interferon etc. is filtered at high recovery rate of the active substance avoiding the adsorption of the active substance onto the filter. By the filtration, harmful viruses such as Creutzfeldt-Jacob disease pathogen which may exist in the physiologically active sub- stance can be removed.

5173420

M O N O C L O N A L A N T I B O D Y R E C O G N I Z I N G U N - N A T U R A L

G A N G L I O S I D E G D 3

Reiji Kannagi, Yoshiko Kirihata, Tomoya Ogawa, Masaaki Numata, Mamoru Sugimoto, Kyoto, Japan assigned to MECT Corporation

A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrow9NeuAc terminal. A monoelonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrowfGal beta terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc al- pha2 right arrow9NeuAc terminal, NeuAc al- pha2 right arrow6Gal beta terminal and NeuAc

PATENT ABSTRACTS

alpha2 right arrowlCer. Hybridomas are pre- pared which produce antibodies A, B and C. A process for producing the hybridomas is dis- closed including the step of fusing a myeloma cell and a B cell (lymphocyte) produced by the im- munization of animal using as an antigen, the sialic acid glycolipid containing at least one epit- ope of the group NeuAc alpha2 fight ar- row9NeuAc terminal, NeuAc alpha2 fight arrow6Gal beta terminal and NeuAc alpha2 fight arrowlCer.

5173422

M O N O C L O N A L A N T I B O D I E S S P E C I F I C F O R H U M A N

G L Y C O A L B U M I N

William Knowles, Vincent Marchesi assigned to Miles Inc

Monoclonal antibodies specific for the glycosylated lysinc residue at position 525 in glycoalbumin'and a method for producing such antibodies. The monoclonal antibodies are use- ful as reagents in immunoassays for the specific determination of glycoalbumin in human blood samples which is indicative of the severity of the diabetic condition. The monoclonal antibodies are secreted by hybridomas obtained by fusing a mycloma cell with a lymphocyte that has been taken from an animal, usually a mouse, im- munized with a peptide immunogen and which produces antibody to the lysine 525 residue in glycoalbumin. The synthetic peptidc immuno- gen comprises a peptide residue which includes an epsilon-amino glucosylated lysine and an ad- jacent amino acid sequence in which at least one of the amino acid units is in a position correspon- ding to the peptide sequence of human albumin adjacent to lysine 525, the glycosylated peptide residue being linked to an immunogenic carrier.

5174993

R E C O M B I N A N T A V I P O X V I R U S A N D I M M U N O L O G I C A L U S E

T H E R E O F

Enzo Paoletti assigned to Health Research lnc

The present invention provides a method for in- ducing an immunological response in a ver- tebrate to a pathogen by inoculating the vertebrate with a synthetic recombinant avipox virus modified by the presence, in a non-essential region of the avipox genome, of DNA from any

365

source which codes for and expresses an antigen of the pathogen. The present invention further provides a synthetic recombinant avipox virus modified by the insertion therein of DNA from any source, and particularly from a non-avipox source, into a non-essential region of the avipox genome.

5175004

P R O P A G A T A B L E , N E W C O M B I N A N T C E L L S F O R

C E L L U L A R R E P L A C E M E N T T H E R A P Y

Kenneth N Matsumura

A method for creating a propagatable, new com- binant cell with differentiated function to replenish dwindling number of similar cells in diseased subjects. The new combinant cell is ob- tained by 1) removing a nucleated cell, which is of the same differentiative phenotype as the dis- eased cells, from a subject and isolating therefrom a karyoplast, 2) isolating from a source other than said subject a proliferation- prone cell which is of the same differentiative phenotyp¢ or which is predestined to become the same phenotype as the diseased cells and isolating therefrom a cytoplast, 3) fusing the cytoplast and karyoplast to form a pro- pagatable, new comhinant cell, 4) propagating the comhinant cell in culture, and 5) trans- planting the combinant cells into said subject. In another embodiment the karyoplast donor is histocompatible to said subject. In yet another embodiment a whole cell is used in lieu of a karyoplast for fusion with the cytoplast.

5175083

I M M U N O A S S A Y F O R T H E Q U A N T I T A T I O N O F H U M A N C 4

G E N E P R O D U C T S

Joann M Moulds assigned to Board of Regents University of Texas

Utilizing mouse monoclonal antibodies which recognize Rodgers 1 and Chido 1 epitopes car- fled on the C4A and C4B molecules, and heat ag- gregated lgG to activate C1, an immunoassay was developed for the quantitation of comple- ment components, including total C4, C4A and C4B. Interassay variation was 12.4%, 11.5% and 10.8%, respectively. The immunoassay was com- pared to the quantitation of total C4 by radial